Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001493152-23-040764
Filing Date
2023-11-14
Accepted
2023-11-14 07:05:50
Documents
76
Period of Report
2023-09-30

Document Format Files

Seq Description Document Type Size
1 form10-q.htm   iXBRL 10-Q 2388746
2 ex10-11.htm EX-10.11 87682
3 ex10-12.htm EX-10.12 88399
4 ex31-1.htm EX-31.1 18949
5 ex31-2.htm EX-31.2 18797
6 ex32-1.htm EX-32.1 10793
  Complete submission text file 0001493152-23-040764.txt   12162971

Data Files

Seq Description Document Type Size
7 XBRL SCHEMA FILE evfm-20230930.xsd EX-101.SCH 79868
8 XBRL CALCULATION FILE evfm-20230930_cal.xml EX-101.CAL 66720
9 XBRL DEFINITION FILE evfm-20230930_def.xml EX-101.DEF 377178
10 XBRL LABEL FILE evfm-20230930_lab.xml EX-101.LAB 596496
11 XBRL PRESENTATION FILE evfm-20230930_pre.xml EX-101.PRE 470959
70 EXTRACTED XBRL INSTANCE DOCUMENT form10-q_htm.xml XML 2357502
Mailing Address 12400 HIGH BLUFF DRIVE SUITE 600 SAN DIEGO CA 92130
Business Address 12400 HIGH BLUFF DRIVE SUITE 600 SAN DIEGO CA 92130 (858) 550-1900
Evofem Biosciences, Inc. (Filer) CIK: 0001618835 (see all company filings)

EIN.: 208527075 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-36754 | Film No.: 231401534
SIC: 2834 Pharmaceutical Preparations